Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.

    Summary
    EudraCT number
    2011-001988-52
    Trial protocol
    BE   DE   GB   AT   NL   FR   NO   SI   IT   PL   DK   SK  
    Global end of trial date
    30 Oct 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    23 May 2024
    First version publication date
    23 May 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    90101
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01524926
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    EORTC
    Sponsor organisation address
    Avenue E Mounier 83/11, Brussels, Belgium, 1200
    Public contact
    Head of Regulatory Affairs, EORTC, 32 27741035, regulatory@eortc.be
    Scientific contact
    Head of Regulatory Affairs, EORTC, 32 27741035, regulatory@eortc.be
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    05 Mar 2021
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    30 Oct 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The study will primarily assess the efficacy of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation, where tyrosine kinase inhibitors against these targets have not yet been adequately explored.
    Protection of trial subjects
    The responsible investigator will ensure that this study is conducted in agreement with either the Declaration of Helsinki (available on the World Medical Association web site (http://www.wma.net)) and/or the laws and regulations of the country, whichever provides the greatest protection of the patient. The protocol has been written, and the study will be conducted according to the ICH Harmonized Tripartite Guideline on Good Clinical Practice (ICH-GCP, available online at https://www.ema.europa.eu/documents/scientific-guideline/ich-e6-r1-guideline-good-clinicalpractice_ en.pdf).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Jun 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 36
    Country: Number of subjects enrolled
    Belgium: 13
    Country: Number of subjects enrolled
    France: 28
    Country: Number of subjects enrolled
    Germany: 45
    Country: Number of subjects enrolled
    Italy: 20
    Country: Number of subjects enrolled
    Netherlands: 11
    Country: Number of subjects enrolled
    Norway: 7
    Country: Number of subjects enrolled
    Poland: 22
    Country: Number of subjects enrolled
    Slovakia: 13
    Country: Number of subjects enrolled
    Slovenia: 3
    Worldwide total number of subjects
    198
    EEA total number of subjects
    162
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    7
    Adults (18-64 years)
    170
    From 65 to 84 years
    21
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Patient recruitment followed a three steps procedure: - step 1: registration - step 2: central histopathology confirmation - step 3: enrollment. Subjects must meet all of the eligibility criteria to be eligible for treatment with crizotinib. Total time between step 1 and step 3, allowing treatment, should not exceed 7 weeks.

    Pre-assignment
    Screening details
    It includes documentation of extent of disease, ophtalmologic examination, ECG, LVEF (echo or MUGA scan), laboratory examinations, documentation of adverse events and concomitant medications. If applicable, a pregnancy.

    Pre-assignment period milestones
    Number of subjects started
    198
    Number of subjects completed
    141

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    Screening failures: 56
    Reason: Number of subjects
    Consent withdrawn by subject: 1
    Period 1
    Period 1 title
    Study period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Anaplastic large cell lymphoma (ALCL)
    Arm description
    ALCL is a rare variant of Non-Hodgkin’s lymphoma associated with ALK alterations in 80-90% of cases diagnosed in adolescents and young adults
    Arm type
    Cohort

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Arm title
    Inflammatory myofibroblastic tumor (IMFT)
    Arm description
    IMFT is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. These tumors occur primarily during the first two decades of life and typically arise in the lung, retroperitoneum, or abdominopelvic region. Abdominal tumors may be multifocal. Lesional cells are predominantly myofibroblasts in a myxoid to collagenous stroma admixed with inflammatory cells. Local recurrence may occur after initial surgery, with a low risk of distant metastases, so that IMFTs are considered to be soft tissue tumors of intermediate biologic potential, with only a small fraction behaving aggressively.
    Arm type
    Cohort

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Arm title
    Papillary renal cell carcinoma type 1 (PRCC)
    Arm description
    PRCC occurs in sporadic and hereditary forms, accounting for 10 to 15% of carcinomas of the renal tubular epithelium. Current classification of a renal tumor as PRCC requires a minimum of 75% papillary or tubulopapillary architecture. Delahunt and Eble proposed a subclassification of PRCCs into type 1 and type 2 tumors, based on histological features.
    Arm type
    Cohort

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Arm title
    Alveolar soft part sarcoma (ASPS)
    Arm description
    ASPS is a clinically and morphologically distinct soft tissue sarcoma first defined and named by Christopherson et al. in 1952. It is an uncommon tumor and uniformly malignant. Its frequency is estimated at 0.5 to 1% of all soft tissue sarcomas and it occurs principally in adolescents and young adults. There are two main locations of the tumor. When it occurs in adults, it is predominantly in the lower extremities, although it has been described in a variety of unusual locations, including the female genital tract, mediastinum, breast, urinary bladder, gastrointestinal tract, and bone. When the tumor affects infants and children, it is often located in the head and neck region, especially the orbit and tongue. ASPS usually presents as a slowly growing, painless mass.
    Arm type
    Cohort

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Arm title
    Clear cell sarcoma (CCSA)
    Arm description
    CCSA is an aggressive soft tissue sarcoma that typically develops in the tendons and aponeuroses of children and young adults. A high rate of local and distant recurrence results in a 5 year overall survival of only 50%. Five year survival decreases to 20% for metastatic disease, consistent with the tumor’s profound resistance to conventional chemotherapy and radiation therapy.
    Arm type
    Cohort

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Arm title
    Alveolar rhabdomyosarcoma (ARMS)
    Arm description
    Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and does also occur in adults. Although the precise cell type from which the tumor originates is still a matter of debate, the evidence points towards the myogenic lineage. Rhabdomyosarcoma expresses a variety of markers typical of both embryonic and mature skeletal muscle. A widely employed histologic classification of rhabdomyosarcomas defines three subtypes, differing from each other for body location, occurrence, mean patient age, and prognosis. The alveolar subtype (ARMS) typically consists of small round densely packed cells, resembling pulmonary alveoli, and it occurs more often in the trunk and extremities. Expression profiling of different subtypes of rhabdomyosarcomas has revealed that their two signatures differ widely.
    Arm type
    Cohort

    Investigational medicinal product name
    Crizotinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    Patients of 15 years old or older Crizotinib will be administered orally at a dose of 250 mg twice daily (BID) at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. Patients younger than 15 years old Crizotinib will be administered orally at a dose of 280 mg/m²/dose BID at approximately the same time each day on a continuous daily dosing schedule, i.e. no break in dosing, in the absence of drug related toxicity. The use of capsules is recommended if the calculated dose with +/-10% can be given by the existing capsules, otherwise it is recommended to use oral solution. Patients unable to swallow should receive the oral solution.

    Number of subjects in period 1 [1]
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Papillary renal cell carcinoma type 1 (PRCC) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Alveolar rhabdomyosarcoma (ARMS)
    Started
    3
    20
    23
    48
    34
    13
    Completed
    3
    20
    23
    48
    34
    13
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Only the 141 patients completing the pre-assignment period entered in this study period.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Anaplastic large cell lymphoma (ALCL)
    Reporting group description
    ALCL is a rare variant of Non-Hodgkin’s lymphoma associated with ALK alterations in 80-90% of cases diagnosed in adolescents and young adults

    Reporting group title
    Inflammatory myofibroblastic tumor (IMFT)
    Reporting group description
    IMFT is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. These tumors occur primarily during the first two decades of life and typically arise in the lung, retroperitoneum, or abdominopelvic region. Abdominal tumors may be multifocal. Lesional cells are predominantly myofibroblasts in a myxoid to collagenous stroma admixed with inflammatory cells. Local recurrence may occur after initial surgery, with a low risk of distant metastases, so that IMFTs are considered to be soft tissue tumors of intermediate biologic potential, with only a small fraction behaving aggressively.

    Reporting group title
    Papillary renal cell carcinoma type 1 (PRCC)
    Reporting group description
    PRCC occurs in sporadic and hereditary forms, accounting for 10 to 15% of carcinomas of the renal tubular epithelium. Current classification of a renal tumor as PRCC requires a minimum of 75% papillary or tubulopapillary architecture. Delahunt and Eble proposed a subclassification of PRCCs into type 1 and type 2 tumors, based on histological features.

    Reporting group title
    Alveolar soft part sarcoma (ASPS)
    Reporting group description
    ASPS is a clinically and morphologically distinct soft tissue sarcoma first defined and named by Christopherson et al. in 1952. It is an uncommon tumor and uniformly malignant. Its frequency is estimated at 0.5 to 1% of all soft tissue sarcomas and it occurs principally in adolescents and young adults. There are two main locations of the tumor. When it occurs in adults, it is predominantly in the lower extremities, although it has been described in a variety of unusual locations, including the female genital tract, mediastinum, breast, urinary bladder, gastrointestinal tract, and bone. When the tumor affects infants and children, it is often located in the head and neck region, especially the orbit and tongue. ASPS usually presents as a slowly growing, painless mass.

    Reporting group title
    Clear cell sarcoma (CCSA)
    Reporting group description
    CCSA is an aggressive soft tissue sarcoma that typically develops in the tendons and aponeuroses of children and young adults. A high rate of local and distant recurrence results in a 5 year overall survival of only 50%. Five year survival decreases to 20% for metastatic disease, consistent with the tumor’s profound resistance to conventional chemotherapy and radiation therapy.

    Reporting group title
    Alveolar rhabdomyosarcoma (ARMS)
    Reporting group description
    Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and does also occur in adults. Although the precise cell type from which the tumor originates is still a matter of debate, the evidence points towards the myogenic lineage. Rhabdomyosarcoma expresses a variety of markers typical of both embryonic and mature skeletal muscle. A widely employed histologic classification of rhabdomyosarcomas defines three subtypes, differing from each other for body location, occurrence, mean patient age, and prognosis. The alveolar subtype (ARMS) typically consists of small round densely packed cells, resembling pulmonary alveoli, and it occurs more often in the trunk and extremities. Expression profiling of different subtypes of rhabdomyosarcomas has revealed that their two signatures differ widely.

    Reporting group values
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Papillary renal cell carcinoma type 1 (PRCC) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Alveolar rhabdomyosarcoma (ARMS) Total
    Number of subjects
    3 20 23 48 34 13 141
    Age categorical
    Age group
    Units: Subjects
        Infants and toddlers (28 days-23 months)
    0 0 0 0 0 0 0
        Children (2-11 years)
    0 0 0 0 0 0 0
        Adolescents (12-17 years)
    1 1 0 1 0 2 5
        Adults (18-64 years)
    2 15 14 46 34 11 122
        From 65-84 years
    0 4 9 1 0 0 14
        85 years and over
    0 0 0 0 0 0 0
    Age continuous
    Age (years)
    Units: years
        median (full range (min-max))
    21 (15 to 24) 45 (15 to 78) 61 (49 to 81) 30.5 (16 to 69) 44 (18 to 64) 30 (16 to 48) -
    Gender categorical
    Gender
    Units: Subjects
        Female
    0 9 3 22 13 2 49
        Male
    3 11 20 26 21 11 92
    ECOG
    Eastern Cooperative Oncology Group (ECOG) performance status / Lansky play scale
    Units: Subjects
        Value 0
    2 11 13 36 17 2 81
        Value 1
    1 8 10 11 12 5 47
        Value 2
    0 1 0 1 5 6 13
    Previous surgery
    Any previous major surgery
    Units: Subjects
        No
    3 10 0 17 2 8 40
        Yes
    0 10 23 31 32 5 101
    Prior systemic anticancer therapy
    Any prior systemic anticancer therapy
    Units: Subjects
        No
    0 12 14 25 25 0 76
        Yes
    3 8 9 23 9 13 65
    Chemotherapy
    Chemotherapy
    Units: Subjects
        No
    0 13 22 37 25 0 97
        Yes
    3 7 1 11 9 13 44
    Any palliative radiotherapy
    Any palliative radiotherapy
    Units: Subjects
        No
    3 18 23 31 22 4 101
        Yes
    0 2 0 17 12 9 40
    Radiotherapy
    Radiotherapy
    Units: Subjects
        No
    3 17 23 23 17 1 84
        Yes
    0 3 0 25 17 12 57
    Immunotherapy
    Immunotherapy
    Units: Subjects
        No
    1 20 22 48 33 13 137
        Yes
    2 0 1 0 1 0 4
    Other anticancer therapy
    Other anticancer therapy
    Units: Subjects
        No
    2 17 14 32 33 12 110
        Yes
    1 3 9 16 1 1 31
    Subject analysis sets

    Subject analysis set title
    Safety population
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who started the treatment

    Subject analysis set title
    Per-Protocol Population
    Subject analysis set type
    Per protocol
    Subject analysis set description
    all eligible and evaluable patients

    Subject analysis set title
    PRCC Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    PRCC Cohort

    Subject analysis set title
    CCSA Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    CCSA Cohort

    Subject analysis set title
    ARMS cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    ARMS Cohort

    Subject analysis set title
    ASPS Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    ASPS Cohort

    Subject analysis set title
    IMFT Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    IMFT Cohort

    Subject analysis sets values
    Safety population Per-Protocol Population PRCC Cohort CCSA Cohort ARMS cohort ASPS Cohort IMFT Cohort
    Number of subjects
    141
    123
    23
    28
    8
    45
    19
    Age categorical
    Age group
    Units: Subjects
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    5
        Adults (18-64 years)
    122
        From 65-84 years
    14
        85 years and over
    0
    Age continuous
    Age (years)
    Units: years
        median (full range (min-max))
    39 (15 to 81)
    39.5 (15 to 81)
    Gender categorical
    Gender
    Units: Subjects
        Female
    49
    44
        Male
    92
    82
    ECOG
    Eastern Cooperative Oncology Group (ECOG) performance status / Lansky play scale
    Units: Subjects
        Value 0
    81
    77
        Value 1
    47
    43
        Value 2
    13
    6
    Previous surgery
    Any previous major surgery
    Units: Subjects
        No
    29
        Yes
    112
    Prior systemic anticancer therapy
    Any prior systemic anticancer therapy
    Units: Subjects
        No
    76
        Yes
    62
    Chemotherapy
    Chemotherapy
    Units: Subjects
        No
    97
        Yes
    44
    Any palliative radiotherapy
    Any palliative radiotherapy
    Units: Subjects
        No
    101
        Yes
    40
    Radiotherapy
    Radiotherapy
    Units: Subjects
        No
    84
        Yes
    57
    Immunotherapy
    Immunotherapy
    Units: Subjects
        No
    137
        Yes
    4
    Other anticancer therapy
    Other anticancer therapy
    Units: Subjects
        No
    110
        Yes
    31

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Anaplastic large cell lymphoma (ALCL)
    Reporting group description
    ALCL is a rare variant of Non-Hodgkin’s lymphoma associated with ALK alterations in 80-90% of cases diagnosed in adolescents and young adults

    Reporting group title
    Inflammatory myofibroblastic tumor (IMFT)
    Reporting group description
    IMFT is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. These tumors occur primarily during the first two decades of life and typically arise in the lung, retroperitoneum, or abdominopelvic region. Abdominal tumors may be multifocal. Lesional cells are predominantly myofibroblasts in a myxoid to collagenous stroma admixed with inflammatory cells. Local recurrence may occur after initial surgery, with a low risk of distant metastases, so that IMFTs are considered to be soft tissue tumors of intermediate biologic potential, with only a small fraction behaving aggressively.

    Reporting group title
    Papillary renal cell carcinoma type 1 (PRCC)
    Reporting group description
    PRCC occurs in sporadic and hereditary forms, accounting for 10 to 15% of carcinomas of the renal tubular epithelium. Current classification of a renal tumor as PRCC requires a minimum of 75% papillary or tubulopapillary architecture. Delahunt and Eble proposed a subclassification of PRCCs into type 1 and type 2 tumors, based on histological features.

    Reporting group title
    Alveolar soft part sarcoma (ASPS)
    Reporting group description
    ASPS is a clinically and morphologically distinct soft tissue sarcoma first defined and named by Christopherson et al. in 1952. It is an uncommon tumor and uniformly malignant. Its frequency is estimated at 0.5 to 1% of all soft tissue sarcomas and it occurs principally in adolescents and young adults. There are two main locations of the tumor. When it occurs in adults, it is predominantly in the lower extremities, although it has been described in a variety of unusual locations, including the female genital tract, mediastinum, breast, urinary bladder, gastrointestinal tract, and bone. When the tumor affects infants and children, it is often located in the head and neck region, especially the orbit and tongue. ASPS usually presents as a slowly growing, painless mass.

    Reporting group title
    Clear cell sarcoma (CCSA)
    Reporting group description
    CCSA is an aggressive soft tissue sarcoma that typically develops in the tendons and aponeuroses of children and young adults. A high rate of local and distant recurrence results in a 5 year overall survival of only 50%. Five year survival decreases to 20% for metastatic disease, consistent with the tumor’s profound resistance to conventional chemotherapy and radiation therapy.

    Reporting group title
    Alveolar rhabdomyosarcoma (ARMS)
    Reporting group description
    Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and does also occur in adults. Although the precise cell type from which the tumor originates is still a matter of debate, the evidence points towards the myogenic lineage. Rhabdomyosarcoma expresses a variety of markers typical of both embryonic and mature skeletal muscle. A widely employed histologic classification of rhabdomyosarcomas defines three subtypes, differing from each other for body location, occurrence, mean patient age, and prognosis. The alveolar subtype (ARMS) typically consists of small round densely packed cells, resembling pulmonary alveoli, and it occurs more often in the trunk and extremities. Expression profiling of different subtypes of rhabdomyosarcomas has revealed that their two signatures differ widely.

    Subject analysis set title
    Safety population
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who started the treatment

    Subject analysis set title
    Per-Protocol Population
    Subject analysis set type
    Per protocol
    Subject analysis set description
    all eligible and evaluable patients

    Subject analysis set title
    PRCC Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    PRCC Cohort

    Subject analysis set title
    CCSA Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    CCSA Cohort

    Subject analysis set title
    ARMS cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    ARMS Cohort

    Subject analysis set title
    ASPS Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    ASPS Cohort

    Subject analysis set title
    IMFT Cohort
    Subject analysis set type
    Per protocol
    Subject analysis set description
    IMFT Cohort

    Primary: Overall Response Rate

    Close Top of page
    End point title
    Overall Response Rate
    End point description
    The primary endpoint overall response is defined as confirmed complete and partial response (RECIST 1.1) observed during the whole treatment period
    End point type
    Primary
    End point timeframe
    The whole treatment period
    End point values
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Papillary renal cell carcinoma type 1 (PRCC) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Alveolar rhabdomyosarcoma (ARMS) PRCC Cohort CCSA Cohort ARMS cohort ASPS Cohort IMFT Cohort
    Number of subjects analysed
    0 [1]
    19
    23
    45
    28
    8
    23
    28
    8
    45
    19
    Units: Subjects
        Reponders
    9
    4
    2
    1
    1
    4
    1
    1
    2
    1
        Non-responders
    10
    19
    43
    27
    7
    19
    27
    7
    43
    27
    Notes
    [1] - Too small sample size for analysis
    Statistical analysis title
    Primary decision rule - PRCC
    Statistical analysis description
    a Simon's optimal two stage design (alpha=beta=0.10) was implemented. The first stage will require 12 eligible and evaluable* patients in each sub-cohort. If at least 2 patients respond, the sub-cohort goes to the second stage and the accrual is continued until 35 eligible and evaluable* patients. At that time, if less than 6 patients respond, the sub-cohort is stopped and will be declared as ineffective. If at least 6 of the 35 patients respond (17%), the sub-cohort will be deemed successfull.
    Comparison groups
    Papillary renal cell carcinoma type 1 (PRCC) v PRCC Cohort
    Number of subjects included in analysis
    46
    Analysis specification
    Pre-specified
    Analysis type
    superiority [2]
    P-value
    = 0 [3]
    Method
    Not Applicable, system blocks otherwise
    Parameter type
    Proportion
    Point estimate
    0.174
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.049
         upper limit
    0.388
    Notes
    [2] - The analysis is done by implementing the decision rule. This is a single arm test - two arms were provided due to EUDRACT reporting system limitation. The primary test is performed in the final decision rule population only.
    [3] - The study did not reach the number of patients needed. The confidence interval of the response rate includes 10% so the arm was not deemed successful.
    Statistical analysis title
    Primary decision rule - CCSA
    Statistical analysis description
    a Simon's optimal two stage design (alpha=beta=0.10) was implemented. The first stage will require 12 eligible and evaluable patients in each sub-cohort. If at least 2 patients respond, the sub-cohort goes to the second stage and the accrual is continued until 35 eligible and evaluable patients. At that time, if less than 6 patients respond, the sub-cohort is stopped and will be declared as ineffective. If at least 6 of the 35 patients respond (17%), the sub-cohort will be deemed successfull.
    Comparison groups
    Clear cell sarcoma (CCSA) v CCSA Cohort
    Number of subjects included in analysis
    56
    Analysis specification
    Pre-specified
    Analysis type
    superiority [4]
    P-value
    = 0 [5]
    Method
    Not Applicable, system blocks otherwise
    Parameter type
    Proportion
    Point estimate
    0.036
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.001
         upper limit
    0.183
    Variability estimate
    Standard deviation
    Dispersion value
    0
    Notes
    [4] - The analysis is done by implementing the decision rule. This is a single arm test - two arms were provided due to EUDRACT reporting system limitation. The primary test is performed in the final decision rule population only.
    [5] - The study did not reach the number of patients needed. The confidence interval of the response rate includes 10% so the arm was not deemed successful.
    Statistical analysis title
    Primary decision rule - ARMS
    Statistical analysis description
    a Simon's optimal two stage design (alpha=beta=0.10) was implemented. The first stage will require 12 eligible and evaluable patients in each sub-cohort. If at least 2 patients respond, the sub-cohort goes to the second stage and the accrual is continued until 35 eligible and evaluable patients. At that time, if less than 6 patients respond, the sub-cohort is stopped and will be declared as ineffective. If at least 6 of the 35 patients respond (17%), the sub-cohort will be deemed successfull.
    Comparison groups
    Alveolar rhabdomyosarcoma (ARMS) v ARMS cohort
    Number of subjects included in analysis
    16
    Analysis specification
    Pre-specified
    Analysis type
    superiority [6]
    P-value
    = 0 [7]
    Method
    Not Applicable, system blocks otherwise
    Parameter type
    Proportion
    Point estimate
    0.125
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.003
         upper limit
    0.526
    Notes
    [6] - The analysis is done by implementing the decision rule. This is a single arm test - two arms were provided due to EUDRACT reporting system limitation. The primary test is performed in the final decision rule population only.
    [7] - The study did not reach the number of patients needed. The confidence interval of the response rate includes 10% so the arm was not deemed successful.
    Statistical analysis title
    Primary decision rule - ASPS
    Statistical analysis description
    a Simon's optimal two stage design (alpha=beta=0.10) was implemented. The first stage will require 12 eligible and evaluable patients in each sub-cohort. If at least 2 patients respond, the sub-cohort goes to the second stage and the accrual is continued until 35 eligible and evaluable patients. At that time, if less than 6 patients respond, the sub-cohort is stopped and will be declared as ineffective. If at least 6 of the 35 patients respond (17%), the sub-cohort will be deemed successfull.
    Comparison groups
    Alveolar soft part sarcoma (ASPS) v ASPS Cohort
    Number of subjects included in analysis
    90
    Analysis specification
    Pre-specified
    Analysis type
    superiority [8]
    P-value
    = 0 [9]
    Method
    Not Applicable, system blocks otherwise
    Parameter type
    Proportion
    Point estimate
    0.044
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0
         upper limit
    0.152
    Notes
    [8] - The analysis is done by implementing the decision rule. This is a single arm test - two arms were provided due to EUDRACT reporting system limitation. The primary test is performed in the final decision rule population only.
    [9] - The confidence interval of the response rate includes 10% so the arm was not deemed successful.
    Statistical analysis title
    Primary decision rule - IMFT
    Statistical analysis description
    a Simon's optimal two stage design (alpha=beta=0.10) was implemented. The first stage will require 12 eligible and evaluable patients in each sub-cohort. If at least 2 patients respond, the sub-cohort goes to the second stage and the accrual is continued until 35 eligible and evaluable patients. At that time, if less than 6 patients respond, the sub-cohort is stopped and will be declared as ineffective. If at least 6 of the 35 patients respond (17%), the sub-cohort will be deemed successfull.
    Comparison groups
    Inflammatory myofibroblastic tumor (IMFT) v IMFT Cohort
    Number of subjects included in analysis
    38
    Analysis specification
    Pre-specified
    Analysis type
    superiority [10]
    P-value
    = 0 [11]
    Method
    Not Applicable, system blocks otherwise
    Parameter type
    Proportion
    Point estimate
    0.474
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.245
         upper limit
    0.711
    Notes
    [10] - The analysis is done by implementing the decision rule. This is a single arm test - two arms were provided due to EUDRACT reporting system limitation. The primary test is performed in the final decision rule population only.
    [11] - The study did not reach the number of patients needed. However, the confidence interval of the response rate includes 10% so the arm was deemed successful.

    Secondary: Overal survival

    Close Top of page
    End point title
    Overal survival
    End point description
    End point type
    Secondary
    End point timeframe
    Overall Survival (OS) is calculated as the time from enrollment to the date of death (any cause). Patients alive at the time of analysis will be censored at the last time they are known to be alive.
    End point values
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Papillary renal cell carcinoma type 1 (PRCC) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Alveolar rhabdomyosarcoma (ARMS)
    Number of subjects analysed
    0 [12]
    19
    23
    45
    28
    8
    Units: Months
        median (confidence interval 95%)
    ( to )
    46.9 (20.2 to 100.0)
    30.5 (12.4 to 74.5)
    60.3 (38.1 to 74.6)
    9.4 (7.6 to 14.5)
    5.1 (.7 to 7)
    Notes
    [12] - Not analyzed due to small sample size
    No statistical analyses for this end point

    Secondary: Progression free survival

    Close Top of page
    End point title
    Progression free survival
    End point description
    End point type
    Secondary
    End point timeframe
    Progression free survival (PFS) will be the time interval between the date of enrollment and the date of disease progression or death (events), whichever comes first. If neither event has been observed, then the patient is censored
    End point values
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Papillary renal cell carcinoma type 1 (PRCC) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Alveolar rhabdomyosarcoma (ARMS)
    Number of subjects analysed
    0 [13]
    19
    23
    45
    28
    8
    Units: Months
        median (confidence interval 95%)
    ( to )
    15.3 (5.6 to 52.6)
    5.8 (2.6 to 28.7)
    8.1 (4.2 to 11.6)
    4.2 (2.2 to 5.5)
    1.2 (0.5 to 1.4)
    Notes
    [13] - Too small sample size for analysis
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events were collected on a CRF to be submitted at pre-specified timepoint.
    Adverse event reporting additional description
    CRF for AEs contains pre-specified items + additional boxes for all "other" AEs. (xx% AEs are reported as "other" and are not reported as not available from the list of SOC). AEs are evaluated using CTC grading, SAEs using MedDra. Non-SAEs has not been collected specifically, all AEs will be reported in non-SAE section.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19
    Reporting groups
    Reporting group title
    Anaplastic large cell lymphoma (ALCL)
    Reporting group description
    Anaplastic large cell lymphoma (ALCL)

    Reporting group title
    Inflammatory myofibroblastic tumor (IMFT)
    Reporting group description
    Inflammatory myofibroblastic tumor (IMFT)

    Reporting group title
    Alveolar rhabdomyosarcoma (ARMS)
    Reporting group description
    Alveolar rhabdomyosarcoma (ARMS)

    Reporting group title
    Alveolar soft part sarcoma (ASPS)
    Reporting group description
    Alveolar soft part sarcoma (ASPS)

    Reporting group title
    Clear cell sarcoma (CCSA)
    Reporting group description
    Clear cell sarcoma (CCSA)

    Reporting group title
    Papillary renal cell carcinoma type 1 (PRCC)
    Reporting group description
    Papillary renal cell carcinoma type 1 (PRCC)

    Serious adverse events
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Alveolar rhabdomyosarcoma (ARMS) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Papillary renal cell carcinoma type 1 (PRCC)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 3 (0.00%)
    6 / 20 (30.00%)
    3 / 13 (23.08%)
    8 / 48 (16.67%)
    8 / 34 (23.53%)
    4 / 23 (17.39%)
         number of deaths (all causes)
    0
    9
    13
    22
    31
    11
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    TUMOUR PAIN
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FIBROMA
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    DEEP VEIN THROMBOSIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPOTENSION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    CHEST PAIN
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PYREXIA
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHILLS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FATIGUE
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    RESPIRATORY FAILURE
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PULMONARY EMBOLISM
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONITIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTERSTITIAL LUNG DISEASE
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HAEMOPTYSIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MEDIASTINAL HAEMORRHAGE
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    HALLUCINATION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    ALANINE AMINOTRANSFERASE INCREASED
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ELECTROCARDIOGRAM QT PROLONGED
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BLOOD CREATININE INCREASED
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ASPARTATE AMINOTRANSFERASE INCREASED
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    REACTIVE GASTROPATHY
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    BRADYCARDIA
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MYOCARDIAL INFARCTION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    SYNCOPE
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    AGRANULOCYTOSIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    OESOPHAGEAL ULCER
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DYSPHAGIA
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NAUSEA
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    ACUTE KIDNEY INJURY
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    SEPSIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RESPIRATORY TRACT INFECTION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    2 / 34 (5.88%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 1
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PHARYNGITIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER RESPIRATORY TRACT INFECTION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DEVICE OCCLUSION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRONCHITIS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ABDOMINAL ABSCESS
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SEPTIC SHOCK
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    DEHYDRATION
    alternative dictionary used: MedDRA 19
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Anaplastic large cell lymphoma (ALCL) Inflammatory myofibroblastic tumor (IMFT) Alveolar rhabdomyosarcoma (ARMS) Alveolar soft part sarcoma (ASPS) Clear cell sarcoma (CCSA) Papillary renal cell carcinoma type 1 (PRCC)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    3 / 3 (100.00%)
    20 / 20 (100.00%)
    13 / 13 (100.00%)
    48 / 48 (100.00%)
    34 / 34 (100.00%)
    23 / 23 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    NEO OTH PAIN AFTER PATHOLOGICAL FRACTURE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    NEO OTH PATHOLOGICAL FRACTURE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    TUMOR PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    2 / 13 (15.38%)
    2 / 48 (4.17%)
    6 / 34 (17.65%)
    0 / 23 (0.00%)
         occurrences all number
    0
    9
    5
    2
    15
    0
    Vascular disorders
    HEMATOMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    2
    0
    HOT FLASHES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    HYPERTENSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    2 / 3 (66.67%)
    4 / 20 (20.00%)
    1 / 13 (7.69%)
    9 / 48 (18.75%)
    5 / 34 (14.71%)
    2 / 23 (8.70%)
         occurrences all number
    4
    48
    1
    19
    11
    4
    HYPOTENSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    LYMPHEDEMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    VAS OTH THORACIC OUTLET
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    VAS OTH LEG VENOUS INSUFFICIENCY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    VAS OTH PETECHIAE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    4
    0
    0
    0
    0
    VAS OTH PULMONARY EMBOLI
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    THROMBOEMBOLIC EVENT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    3 / 34 (8.82%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    1
    4
    0
    Surgical and medical procedures
    SUR OTH POSTOPERATIVE PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    General disorders and administration site conditions
    CHILLS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    EDEMA FACE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    3
    3
    6
    0
    3
    EDEMA LIMBS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    12 / 20 (60.00%)
    2 / 13 (15.38%)
    8 / 48 (16.67%)
    11 / 34 (32.35%)
    11 / 23 (47.83%)
         occurrences all number
    0
    35
    3
    28
    33
    114
    FATIGUE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    12 / 20 (60.00%)
    7 / 13 (53.85%)
    21 / 48 (43.75%)
    20 / 34 (58.82%)
    13 / 23 (56.52%)
         occurrences all number
    1
    155
    16
    126
    93
    164
    FEVER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    2 / 13 (15.38%)
    9 / 48 (18.75%)
    6 / 34 (17.65%)
    2 / 23 (8.70%)
         occurrences all number
    0
    3
    3
    16
    11
    4
    GEN OTH NIGHT SWEATS (INTERMITTENT)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    GEN OTH ANASARCA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    GEN OTH DETERIORATION OF GENERAL CONDITION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    GEN OTH INFLAMMATORY SYNDROME
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    GEN OTH NIGHT SWEAT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    5 / 34 (14.71%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    7
    0
    GEN OTH NIGHT SWEATS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    6
    0
    0
    0
    0
    FLU LIKE SYMPTOMS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences all number
    0
    4
    0
    2
    4
    0
    GEN OTH PAINFUL SWELLING ABOVE RIGHT CLAVICLE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    GEN OTH SWEAT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    GEN OTH WORSENING OF GENERAL CONDITION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    2
    2
    2
    0
    0
    2
    MALAISE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    NON-CARDIAC CHEST PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    5 / 48 (10.42%)
    3 / 34 (8.82%)
    3 / 23 (13.04%)
         occurrences all number
    0
    3
    4
    5
    8
    5
    PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    5 / 20 (25.00%)
    2 / 13 (15.38%)
    1 / 48 (2.08%)
    2 / 34 (5.88%)
    1 / 23 (4.35%)
         occurrences all number
    0
    13
    3
    2
    4
    1
    Immune system disorders
    ALLERGIC REACTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    IMM OTH ALLERGY OF FARINE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Reproductive system and breast disorders
    BREAST PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    2
    0
    0
    ERECTILE DYSFUNCTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    3
    0
    GYNECOMASTIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    10
    0
    0
    IRREGULAR MENSTRUATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    3
    0
    PELVIC PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    VAGINAL DISCHARGE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    VAGINAL HEMORRHAGE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    Respiratory, thoracic and mediastinal disorders
    COUGH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    4 / 20 (20.00%)
    1 / 13 (7.69%)
    16 / 48 (33.33%)
    10 / 34 (29.41%)
    5 / 23 (21.74%)
         occurrences all number
    3
    16
    1
    47
    23
    17
    DYSPNEA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    5 / 20 (25.00%)
    5 / 13 (38.46%)
    8 / 48 (16.67%)
    12 / 34 (35.29%)
    7 / 23 (30.43%)
         occurrences all number
    0
    13
    5
    23
    22
    23
    EPISTAXIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    HICCUPS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    HOARSENESS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    MEDIASTINAL HEMORRHAGE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    ALLERGIC RHINITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    PHARYNGOLARYNGEAL PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    PLEURAL EFFUSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    2 / 3 (66.67%)
    2 / 20 (10.00%)
    2 / 13 (15.38%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    2 / 23 (8.70%)
         occurrences all number
    2
    2
    2
    0
    1
    2
    RES OTH PULMONARY DISCOMFORT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    PNEUMONITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    3 / 34 (8.82%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    3
    3
    0
    PNEUMOTHORAX
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    RES OTH BRONCHITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    2
    2
    2
    RES OTH BRONCHORRHEA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    RES OTH CRIZOTINIB INDUCED INTERSTITIAL LUNG DISEASE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    RES OTH DECREASED BREATH SOUNDS IN A STRAIGHT BASE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    RES OTH DECREASED BREATH SOUNDS IN RIGHT BASE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    RES OTH HEMOPTYSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    3 / 48 (6.25%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    RES OTH HEMOPTYSIS (PERIODIC)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    RES OTH INTERSTITIAL LUNG DISEASE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    RES OTH PHARYNGODYNIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    RES OTH PNEUMONIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    PLEURITIC PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    16
    0
    RES OTH TACHYPNEA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    RES OTH TONSILLITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    RESPIRATORY FAILURE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    SORE THROAT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    3 / 48 (6.25%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    3
    0
    0
    VOICE ALTERATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    WHEEZING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    Psychiatric disorders
    INSOMNIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    1 / 13 (7.69%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    2
    3
    1
    0
    2
    ANXIETY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    17
    0
    2
    1
    0
    DEPRESSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    6
    1
    0
    PSY OTH MOOD SWINGS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    PSY OTH SADNESS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    0
    0
    0
    PSY OTH SLEEP DISORDER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    Investigations
    BLOOD PROLACTIN ABNORMAL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    CHOLESTEROL HIGH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    SERUM AMYLASE INCREASED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    ELECTROCARDIOGRAM QT CORRECTED INTERVAL PROLONGED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    6 / 48 (12.50%)
    2 / 34 (5.88%)
    1 / 23 (4.35%)
         occurrences all number
    0
    2
    0
    9
    3
    2
    GGT INCREASED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    0
    7
    0
    0
    1
    1
    INV OTH AGRANULOCYTOSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    INV OTH CRP INCREASED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    LIPASE INCREASED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    CREATININE INCREASED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    WEIGHT LOSS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    WEIGHT GAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    6 / 20 (30.00%)
    0 / 13 (0.00%)
    4 / 48 (8.33%)
    4 / 34 (11.76%)
    1 / 23 (4.35%)
         occurrences all number
    0
    35
    0
    10
    18
    1
    WEIGHT LOSS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    6 / 20 (30.00%)
    2 / 13 (15.38%)
    10 / 48 (20.83%)
    6 / 34 (17.65%)
    1 / 23 (4.35%)
         occurrences all number
    12
    15
    4
    28
    11
    1
    Injury, poisoning and procedural complications
    BURN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    FALL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    FRACTURE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    3
    0
    INJ OTH BLOCKED CATHETER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INJ OTH TICK BITE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Cardiac disorders
    CAR OTH BRADYCARDIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    CAR OTH CARDIAC SLOWING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    CAR OTH DECREASED HEART RATE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    CAR OTH TACHYSYSTOLIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    CAR OTH HEART MURMUR
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    CAR OTH MITRAL MURMUR
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    CAR OTH SLOW-R-PROGRESSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    CAR OTH TACHYCARDIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    CAR OTH DIASTOLIC DYSFUNCTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    MYOCARDIAL INFARCTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    PALPITATIONS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    PERICARDIAL EFFUSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    SINUS BRADYCARDIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    0 / 13 (0.00%)
    5 / 48 (10.42%)
    2 / 34 (5.88%)
    5 / 23 (21.74%)
         occurrences all number
    0
    5
    0
    22
    22
    61
    SINUS TACHYCARDIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    1
    0
    Nervous system disorders
    AMNESIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    COGNITIVE DISTURBANCE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    5
    0
    0
    0
    0
    CONCENTRATION IMPAIRMENT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    DIZZINESS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    1 / 13 (7.69%)
    7 / 48 (14.58%)
    2 / 34 (5.88%)
    1 / 23 (4.35%)
         occurrences all number
    0
    10
    1
    22
    5
    1
    DYSGEUSIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    5 / 20 (25.00%)
    1 / 13 (7.69%)
    8 / 48 (16.67%)
    6 / 34 (17.65%)
    5 / 23 (21.74%)
         occurrences all number
    0
    16
    3
    23
    18
    18
    HEADACHE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    4 / 20 (20.00%)
    0 / 13 (0.00%)
    8 / 48 (16.67%)
    3 / 34 (8.82%)
    1 / 23 (4.35%)
         occurrences all number
    0
    17
    0
    24
    8
    9
    INTRACRANIAL HEMORRHAGE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    LETHARGY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    NER OTH ORTHOSTATISM
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    4
    4
    4
    0
    0
    4
    NER OTH RESTLESS LEGS SYNDROME
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    2
    2
    0
    NER OTH SCIATICA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    NER OTH SENSITIVITY STROBE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    NER OTH TASTE DISORDERS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    NER OTH TINGLING IN LEGS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    NER OTH WEAKNESS LEFT ARM
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    PARESTHESIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences all number
    0
    7
    0
    5
    17
    0
    PERIPHERAL MOTOR NEUROPATHY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    5
    0
    0
    0
    0
    RECURRENT LARYNGEAL NERVE PALSY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    SOMNOLENCE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    4
    0
    SYNCOPE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    TREMOR
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    4
    0
    0
    0
    0
    PERIPHERAL SENSORY NEUROPATHY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    6 / 20 (30.00%)
    1 / 13 (7.69%)
    4 / 48 (8.33%)
    1 / 34 (2.94%)
    2 / 23 (8.70%)
         occurrences all number
    0
    13
    1
    22
    1
    8
    Blood and lymphatic system disorders
    ANEMIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    FEBRILE NEUTROPENIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    Ear and labyrinth disorders
    HEARING IMPAIRED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    VERTIGO
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    TINNITUS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    9
    0
    0
    0
    0
    Eye disorders
    CATARACT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    BLURRED VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    9 / 20 (45.00%)
    1 / 13 (7.69%)
    24 / 48 (50.00%)
    8 / 34 (23.53%)
    8 / 23 (34.78%)
         occurrences all number
    1
    42
    2
    83
    15
    34
    CONJUNCTIVITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    EYE OTH EYE DISORDER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    10
    0
    0
    0
    0
    EYE OTH LEFT EYE VISION IMPAIRED DUE TO TUMOUR
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    EYE OTH SMALL DISTURBANCES OF VISION ON WAKING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    EYE OTH ALTERED PERIPHERAL VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    6
    0
    EYE OTH BILATERAL MEIBOMITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH BURNING OF EYES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    EYE OTH BURNING SENSATION IN EYES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    7
    0
    EYE OTH COTTONWOOL SPOT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    EYE OTH DECREASED VISUAL ACUITY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH DETERIORATING EYESIGHT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH DIPLOPIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    2
    1
    0
    EYE OTH DOUBLE VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    5
    0
    0
    EYE OTH EXOPHORIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    DRY EYE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    4 / 20 (20.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    10
    0
    0
    0
    0
    EYE OTH EYE STRAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH FLICKERING VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    EYE OTH GHOSTING WHEN GOING FROM DARK
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    EYE OTH INCREASED TENSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    EYE OTH INTERMITTENT VISUAL DISTURBANCE/TUNNEL VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    14
    0
    EYE OTH ITCHY EYES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    EYE OTH PRESSURE ABOVE EYES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH MIOSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH OCCULAR FATIGUE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH OVERCORRECTED MYOPIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH PALINOPSIA (AFTERIMAGES)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    22
    0
    0
    EYE OTH PERSISTENCE OF VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    EYE OTH PHOSPHENE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    EYE OTH LOSS OF VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    EYE OTH SMALL DISTURBANCES OF VISION ON WAKING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    11
    EYE OTH SORE EYES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    EYE OTH STROBING VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    0
    0
    22
    EYE OTH VISION DISORDERS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    EYE OTH VISUAL AFTERGLOW ON WAKING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    EYE OTH VISUAL DISORDER (UNSTABLE IMAGES)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    4
    0
    FLASHING LIGHTS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    0 / 13 (0.00%)
    7 / 48 (14.58%)
    3 / 34 (8.82%)
    1 / 23 (4.35%)
         occurrences all number
    0
    3
    0
    64
    8
    1
    EYE OTH VISUAL DISTURBANCES ON WAKING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    EYE OTH VISUAL FIELD LOSS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    EYE OTH VISUAL IMPAIRMENT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    2
    2
    2
    0
    1
    2
    EYE OTH VISUAL LOSS OF 0,4
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    EYE OTH VISUAL PERSISTENCE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    5
    EYE OTH VISUAL DISORDERS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    17
    FLOATERS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    3 / 48 (6.25%)
    0 / 34 (0.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    0
    0
    17
    0
    32
    GLAUCOMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    KERATITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    OPTIC NERVE DISORDER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    4 / 48 (8.33%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    13
    1
    0
    PAPILLEDEMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    PHOTOPHOBIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    WATERING EYES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    1
    1
    STROBING VISION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    Gastrointestinal disorders
    DENTAL CARIES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    ABDOMINAL DISTENSION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    1
    2
    0
    ABDOMINAL PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    6 / 20 (30.00%)
    1 / 13 (7.69%)
    9 / 48 (18.75%)
    7 / 34 (20.59%)
    5 / 23 (21.74%)
         occurrences all number
    0
    24
    1
    20
    23
    9
    ASCITES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    3
    3
    3
    0
    0
    3
    BLOATING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    5
    1
    0
    1
    0
    CONSTIPATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    9 / 20 (45.00%)
    7 / 13 (53.85%)
    18 / 48 (37.50%)
    15 / 34 (44.12%)
    12 / 23 (52.17%)
         occurrences all number
    0
    59
    9
    68
    36
    40
    DIARRHEA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    9 / 20 (45.00%)
    3 / 13 (23.08%)
    20 / 48 (41.67%)
    12 / 34 (35.29%)
    10 / 23 (43.48%)
         occurrences all number
    0
    26
    7
    124
    35
    137
    DRY MOUTH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    DYSPEPSIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    0 / 13 (0.00%)
    6 / 48 (12.50%)
    4 / 34 (11.76%)
    0 / 23 (0.00%)
         occurrences all number
    0
    7
    0
    14
    8
    0
    DYSPHAGIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    0
    6
    0
    ESOPHAGEAL PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    3 / 48 (6.25%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    ESOPHAGEAL ULCER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    GAS OTH INDIGESTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    FLATULENCE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    13
    0
    4
    3
    0
    GAS OTH DIGESTIVE TROUBLE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    GAS OTH ABDOMINAL ABCESS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    GAS OTH ABDOMINAL CRAMP
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    GAS OTH ACID REGURGITATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    GAS OTH GINGIVITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    ESOPHAGITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    1 / 13 (7.69%)
    3 / 48 (6.25%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    0
    11
    3
    3
    1
    2
    GAS OTH MUCOSITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    GAS OTH ODYNOPHAGIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    GAS OTH STOMACH CRAMPS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    5
    0
    0
    GAS OTH STOMACH TROUBLE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    GAS OTH TYPE C GASTRITIS WITH ULCERATIVE LESIONS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    GASTRITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    2
    0
    2
    STOMACH PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    3 / 48 (6.25%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    6
    2
    1
    GASTROINTESTINAL PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    4
    0
    0
    HEMORRHOIDS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    0
    0
    0
    0
    MUCOSITIS ORAL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    2
    0
    4
    0
    2
    NAUSEA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    11 / 20 (55.00%)
    8 / 13 (61.54%)
    34 / 48 (70.83%)
    20 / 34 (58.82%)
    11 / 23 (47.83%)
         occurrences all number
    0
    44
    11
    97
    57
    29
    RECTAL HEMORRHAGE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    GASTROESOPHAGEAL REFLUX DISEASE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    4
    0
    2
    2
    0
    VOMITING
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    8 / 20 (40.00%)
    4 / 13 (30.77%)
    24 / 48 (50.00%)
    15 / 34 (44.12%)
    4 / 23 (17.39%)
         occurrences all number
    0
    25
    5
    63
    24
    5
    Hepatobiliary disorders
    HEP OTH CIRRHOSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    HEP OTH HEPATOPATHY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    HEPATIC FAILURE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    HEP OTH CHOLESTASIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    PHOTOSENSITIVITY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    5
    1
    0
    DRY SKIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    2 / 34 (5.88%)
    2 / 23 (8.70%)
         occurrences all number
    0
    5
    0
    2
    3
    13
    ERYTHEMA MULTIFORME
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    6
    0
    0
    HIRSUTISM
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    HYPERHIDROSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    PERIORBITAL EDEMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    3
    0
    ALOPECIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    2 / 13 (15.38%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    5
    4
    13
    2
    0
    PRURITUS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    4 / 20 (20.00%)
    0 / 13 (0.00%)
    4 / 48 (8.33%)
    2 / 34 (5.88%)
    1 / 23 (4.35%)
         occurrences all number
    1
    6
    0
    11
    2
    1
    RASH MACULO-PAPULAR
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 20 (15.00%)
    0 / 13 (0.00%)
    7 / 48 (14.58%)
    3 / 34 (8.82%)
    3 / 23 (13.04%)
         occurrences all number
    0
    13
    0
    13
    8
    8
    SKI OTH ACNE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    SKI OTH ACNE SPINE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    SKI OTH COLD HANDS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    SKI OTH CUTANEOUS ERYTHEMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    SKI OTH HIVES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    SKI OTH CUTANEOUS LESION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    SKI OTH CUTANEOUS RASH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    SKI OTH ECZEMA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    SKI OTH ECZEMA (THIGH)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    SKI OTH FACE HIVES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    SKI OTH HAIR DEVELOPMENT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    SKI OTH CUTANEOUS ERYTHEMA OF THE LEFT LOMBAR FOSSA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    SKI OTH LEFT KNEE SUBCUTANEOUS ABCESS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    SKI OTH NAIL CHANGES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    10
    SKI OTH PANNICULITIS LEFT THIGH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    SKI OTH PSORIATIC RASH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    7
    SKI OTH RASH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    SKI OTH RIGHT LOWER LEG RASH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    10
    0
    SKI OTH SEVERAL RED PAPULES
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    SKI OTH SKIN RASH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    SKIN HYPERPIGMENTATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    SKIN HYPOPIGMENTATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    URTICARIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    9
    0
    1
    0
    0
    SKI OTH SEBORRHEA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Renal and urinary disorders
    ACUTE KIDNEY INJURY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    11
    CHRONIC KIDNEY DISEASE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    3
    0
    0
    0
    HEMATURIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    REN OTH ACUTE RENAL INSUFICIENCY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    REN OTH BLADDER PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    RENAL CYST(S)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    59
    URINARY FREQUENCY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    1
    0
    2
    URINARY INCONTINENCE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    3
    0
    3
    URINARY URGENCY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    REN OTH ACUTE RENAL INSUFFICIENCY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    Endocrine disorders
    END OTH DIABETES INSIPIDUS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    4
    0
    0
    0
    0
    END OTH LOW TESTOSTERONE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    7
    0
    0
    HYPOTHYROIDISM
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    Musculoskeletal and connective tissue disorders
    ARTHRALGIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    6 / 20 (30.00%)
    0 / 13 (0.00%)
    5 / 48 (10.42%)
    4 / 34 (11.76%)
    2 / 23 (8.70%)
         occurrences all number
    0
    11
    0
    15
    19
    16
    BACK PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    6 / 48 (12.50%)
    3 / 34 (8.82%)
    2 / 23 (8.70%)
         occurrences all number
    0
    6
    2
    8
    7
    2
    BONE PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    6 / 48 (12.50%)
    3 / 34 (8.82%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    14
    6
    7
    BUTTOCK PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    CHEST WALL PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    3
    3
    3
    0
    0
    3
    FLANK PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    GENERALIZED MUSCLE WEAKNESS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MUS OTH CRAMPS LOWER LEG, LEFT
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    MUS OTH ACHING LEGS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    MUS OTH CRAMP
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    7
    0
    0
    1
    0
    MUS OTH CRAMPS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    MUS OTH CRAMPS (INTERMITTENT)
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH CRAMPS IN THE CALF LEVEL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    15
    MUS OTH CRAMPS LEFT LEG
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    MUS OTH PAIN STERNUM
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MUS OTH PAIN LEFT GROIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    MUS OTH PAIN OF LEFT AXILLA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MUS OTH FIBROTIC LESION OUTSIDE THE LIVER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH GROIN PAIN AMBILATERAL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MUS OTH HARD MASS IN THE CALF
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH INGUINAL PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    MUS OTH PAIN INGUINAL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MUS OTH LEFT LOIN PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH LEFT LOWER LIMB
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MUS OTH LEG CRAMPS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    MUS OTH MUSCLE CRAMPS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    MUS OTH MUSCLES CRAMPS LEGS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH MUSCLES CRAMPS RIGHT LEG
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    MUS OTH INTERSCAPULAR PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH PAIN OF RIGHT HIP
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    MUS OTH PAIN RIGHT GROIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    MUS OTH PAIN UNDER RIGHT RIBS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH RIGHT SHOULDER TENDINITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    MUS OTH SARCOPENIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    MUS OTH SHOULDER PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MUS OTH UPPER LEG PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    MUSCLE WEAKNESS LOWER LIMB
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    8
    0
    0
    MUSCLE WEAKNESS UPPER LIMB
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    MYALGIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 20 (10.00%)
    1 / 13 (7.69%)
    3 / 48 (6.25%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    2
    5
    0
    0
    NECK PAIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    2
    2
    2
    7
    2
    2
    PAIN IN EXTREMITY
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    4 / 48 (8.33%)
    3 / 34 (8.82%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    17
    4
    0
    MUS OTH SPASM IN BOTH LEGS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    Infections and infestations
    BLADDER INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    ABDOMINAL INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    BRONCHIAL INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    0
    2
    0
    1
    1
    1
    ENTEROCOLITIS INFECTIOUS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    INF OTH BILATERAL VIRAL KERATOCONJUNCTIVITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    INF OTH CANDIDA IN UPPER RESPIRATORY TRACT INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    INF OTH CHEST DRAIN SITE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH CHEST INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    2 / 34 (5.88%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    INF OTH INFLUENZA WITH FEVER
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH COMMON COLD
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    5 / 48 (10.42%)
    5 / 34 (14.71%)
    2 / 23 (8.70%)
         occurrences all number
    2
    2
    0
    11
    6
    10
    INF OTH EAR INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    INF OTH HELICOBACTER PYLORI INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    INF OTH INFECTION OF UNKNOWN ORIGIN
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH INFECTION PROBABLY VIRAL
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    INF OTH INFECTIOUS COLITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    INF OTH COLD SORE
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    INF OTH ORAL MYCOSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    6
    0
    0
    0
    0
    INF OTH ORAL THRUSH
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH PNEUMONIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH RESPIRATORY INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    2
    2
    2
    0
    0
    2
    INF OTH RHINITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    INF OTH SEPTIC SHOCK
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    INF OTH THRUSHESOPHAGITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH LOWER RESPIRATORY TRACT INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH ORAL CANDIDIASIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    INF OTH VIROSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    LARYNGITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    LUNG INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    0
    2
    0
    3
    1
    1
    OTITIS EXTERNA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    PHARYNGITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    SINUSITIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    SKIN INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    16
    0
    0
    TOOTH INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    UPPER RESPIRATORY INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    3 / 20 (15.00%)
    0 / 13 (0.00%)
    2 / 48 (4.17%)
    3 / 34 (8.82%)
    0 / 23 (0.00%)
         occurrences all number
    3
    6
    0
    2
    3
    0
    URINARY TRACT INFECTION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    1 / 48 (2.08%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    2
    0
    1
    0
    1
    SEPSIS
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    Metabolism and nutrition disorders
    ANOREXIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    2 / 20 (10.00%)
    5 / 13 (38.46%)
    12 / 48 (25.00%)
    10 / 34 (29.41%)
    5 / 23 (21.74%)
         occurrences all number
    1
    6
    13
    34
    40
    16
    DEHYDRATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    2 / 13 (15.38%)
    2 / 48 (4.17%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    3
    2
    1
    0
    HYPERGLYCEMIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    HYPOPHOSPHATEMIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    MET OTH HYDROPIC DECOMPENSATION
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 20 (5.00%)
    1 / 13 (7.69%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    1
    1
    1
    0
    0
    1
    MET OTH HYPERLIPIDEMIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    0 / 34 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    0
    5
    0
    0
    0
    0
    MET OTH LOW VITAMIN D
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    MET OTH SERUM IRON DECREASED
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 20 (0.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    HYPOMAGNESEMIA
    alternative dictionary used: CTCAE 4
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 20 (5.00%)
    0 / 13 (0.00%)
    0 / 48 (0.00%)
    1 / 34 (2.94%)
    1 / 23 (4.35%)
         occurrences all number
    0
    4
    0
    0
    1
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    28 Mar 2014
    After one year of recruitment, it appears that the recruitment is faster and that the prevalence of ALK/MET+ patients is higher than expected for part of the cohorts (almost 90% in at least 2 cohorts). In addition, because the whole treatment duration is defined as assessment period for response evaluation, response in some patients requires a very long observation time in particular as some patients may remain in stable disease for a long period and then switch very late to either progression (best response being then SD) or response (best response being then response). Therefore the protocol was amendment to not stop the recruitment once stage I was reached.
    26 Mar 2015
    The objective of this amendment is to permit young patient population (below 15 yo) to be enrolled in this protocol.
    06 Feb 2017
    The following changes were made: -Background section -Eligibility criteria (mainly focusing on restriction for cardiac events) - Clinically normal cardiac function based on the institutional lower limit of normal (LVEF assessed by MUGA or ECHO) and normal 12 lead ECG. - Machine-read ECG QTcF interval ≤470 msec. Periodic monitoring of cardiac function will be performed by ECG and LVEF at baseline and for all patients on treatment: o 12 lead ECG then triplicate set on Day 1 of Cycles 1, 2 & 3 and thereafter every 4 cycles. o LVEF every 3 cycles , more frequently if clinically indicated and at the end of the treatment
    09 Feb 2021
    Pfizer notified us recently about an important safety information regarding ocular toxicity with Xalkori® (crizotinib) in patients with anaplastic large cell lymphoma (ALCL). In a study of 121 patients who were ≤ 21 years of age treated with Xalkori®, 26 patients with ALCL were included and vision disorders were reported in 65% of these patients. The most common visual symptoms were blurred vision and visual impairment with median onset of approximately 1 week. Other visual symptoms included photopsia, vitreous floaters, and photophobia.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:14:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA